JP2005508961A5 - - Google Patents

Download PDF

Info

Publication number
JP2005508961A5
JP2005508961A5 JP2003535784A JP2003535784A JP2005508961A5 JP 2005508961 A5 JP2005508961 A5 JP 2005508961A5 JP 2003535784 A JP2003535784 A JP 2003535784A JP 2003535784 A JP2003535784 A JP 2003535784A JP 2005508961 A5 JP2005508961 A5 JP 2005508961A5
Authority
JP
Japan
Prior art keywords
group
groups
substituted
alkyl
carbon atoms
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2003535784A
Other languages
English (en)
Japanese (ja)
Other versions
JP4484515B2 (ja
JP2005508961A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2002/032834 external-priority patent/WO2003032981A1/en
Publication of JP2005508961A publication Critical patent/JP2005508961A/ja
Publication of JP2005508961A5 publication Critical patent/JP2005508961A5/ja
Application granted granted Critical
Publication of JP4484515B2 publication Critical patent/JP4484515B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2003535784A 2001-10-16 2002-10-16 神経病症候群の治療の為のpde−4阻害剤としての、4−(4−アルコキシ−3−ヒドロキシフェニル)−2−ピロリディン誘導体。 Expired - Fee Related JP4484515B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32931401P 2001-10-16 2001-10-16
PCT/US2002/032834 WO2003032981A1 (en) 2001-10-16 2002-10-16 4-(4-alkoxy-3-hydroxyphenyl)-2-pyrrolidone derivatives as pde-4 inhibitors for the treatment of neurological syndromes

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2009205533A Division JP2009286797A (ja) 2001-10-16 2009-09-07 神経病症候群の治療の為のpde−4阻害剤としての、4−(4−アルコキシ−3−ヒドロキシフェニル)−2−ピロリディン誘導体。

Publications (3)

Publication Number Publication Date
JP2005508961A JP2005508961A (ja) 2005-04-07
JP2005508961A5 true JP2005508961A5 (enExample) 2010-03-18
JP4484515B2 JP4484515B2 (ja) 2010-06-16

Family

ID=23284824

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2003535784A Expired - Fee Related JP4484515B2 (ja) 2001-10-16 2002-10-16 神経病症候群の治療の為のpde−4阻害剤としての、4−(4−アルコキシ−3−ヒドロキシフェニル)−2−ピロリディン誘導体。
JP2009205533A Pending JP2009286797A (ja) 2001-10-16 2009-09-07 神経病症候群の治療の為のpde−4阻害剤としての、4−(4−アルコキシ−3−ヒドロキシフェニル)−2−ピロリディン誘導体。

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2009205533A Pending JP2009286797A (ja) 2001-10-16 2009-09-07 神経病症候群の治療の為のpde−4阻害剤としての、4−(4−アルコキシ−3−ヒドロキシフェニル)−2−ピロリディン誘導体。

Country Status (20)

Country Link
US (3) US7235579B2 (enExample)
EP (1) EP1435944B1 (enExample)
JP (2) JP4484515B2 (enExample)
KR (2) KR100951218B1 (enExample)
CN (1) CN1604776A (enExample)
AT (1) ATE444065T1 (enExample)
AU (1) AU2002335015B8 (enExample)
BR (1) BR0213660A (enExample)
CA (1) CA2463469A1 (enExample)
CO (1) CO5570674A2 (enExample)
DE (1) DE60233884D1 (enExample)
ES (1) ES2334650T3 (enExample)
HR (1) HRP20040409A2 (enExample)
IL (1) IL161317A0 (enExample)
MX (1) MXPA04003516A (enExample)
NO (1) NO20042024L (enExample)
NZ (1) NZ532288A (enExample)
RU (2) RU2340600C2 (enExample)
WO (1) WO2003032981A1 (enExample)
ZA (1) ZA200402856B (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9931318B2 (en) 2003-04-08 2018-04-03 Dart Neuroscience (Cayman) Ltd. Phosphodiesterase 4 inhibitors for cognitive and motor rehabilitation
US8153646B2 (en) 2000-08-10 2012-04-10 Dart Neuroscience (Cayman) Ltd. Phosphodiesterase 4 inhibitors for cognitive and motor rehabilitation
DE60140074D1 (de) * 2000-12-14 2009-11-12 Burnham Inst Non-apoptotische formen des zelltods und verfahren zur modulation
ATE444065T1 (de) 2001-10-16 2009-10-15 Memory Pharm Corp 4(4-alkoxy-3-hydroxyphenyl)-2-pyrrolidon-deriva e als pde-4-hemmer zur behandlung von neurologischen syndromen
US20030157053A1 (en) * 2002-02-19 2003-08-21 Sabina Sperandio Modulators of paraptosis and related methods
US7495016B2 (en) 2002-10-21 2009-02-24 Irm Llc Pyrrolidones with anti-HIV activity
ES2211344B1 (es) * 2002-12-26 2005-10-01 Almirall Prodesfarma, S.A. Nuevos derivados de piridazin-3(2h)-ona.
SG169900A1 (en) * 2003-04-16 2011-04-29 Memory Pharm Corp 4 - (3,4 - disubstituted phenyl) - pyrrolidin-2-one compounds as phosphodiesterase 4 inhibitors
EP1624873A2 (en) * 2003-04-28 2006-02-15 AB Science Use of tyrosine kinase inhibitors for treating cerebral ischemia
ES2251866B1 (es) * 2004-06-18 2007-06-16 Laboratorios Almirall S.A. Nuevos derivados de piridazin-3(2h)-ona.
ES2251867B1 (es) * 2004-06-21 2007-06-16 Laboratorios Almirall S.A. Nuevos derivados de piridazin-3(2h)-ona.
DOP2005000123A (es) * 2004-07-02 2011-07-15 Merck Sharp & Dohme Inhibidores de cetp
EP1802615A1 (en) * 2004-10-20 2007-07-04 Memory Pharmaceuticals Corporation Phosphodiesterase 4 inhibitors
USRE46792E1 (en) * 2005-11-15 2018-04-17 Otsuka Pharmaceutical Co., Ltd. Oxazole compound and pharmaceutical composition
BRPI0620752A2 (pt) * 2005-12-30 2011-11-22 Merck & Co Inc composto ou sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e, uso do composto ou um sal farmaceuticamente aceitável do mesmo
ES2412481T3 (es) * 2006-05-19 2013-07-11 Dart Neuroscience Llc Inhibidores de la fosfodiesterasa 4 para la rehabilitación motora
ES2320954B1 (es) * 2007-03-02 2010-03-16 Laboratorio Almirall S.A. Nuevo procedimiento de preparacion de 3-metil-4-fenilisoxazolo (3,4-d)iridazin-7(6h)-ona.
WO2009067607A2 (en) * 2007-11-20 2009-05-28 Memory Pharmaceuticals Corporation Combinations of pde4 inhibitors and antipsychotics for the treatment of psychotic disorders
ES2865504T3 (es) 2008-10-16 2021-10-15 Univ Johns Hopkins Procedimientos y composiciones para la mejora de la función cognitiva
US20100159034A1 (en) * 2008-12-15 2010-06-24 Auspex Pharmaceuticals, Inc. Pyrrolidinone inhibitors of pde-4
CA2765015C (en) * 2009-06-18 2020-05-05 Concert Pharmaceuticals, Inc. Deuterated isoindoline-1,3-dione derivatives as pde4 and tnf-alpha inhibitors
EP2919788A4 (en) 2012-11-14 2016-05-25 Univ Johns Hopkins METHOD AND COMPOSITIONS FOR TREATING SCHIZOPHRENIA
MD20150071A2 (ro) 2013-02-19 2016-02-29 Pfizer Inc. Compuşi azabenzimidazolici ca inhibitori ai PDE4 izoenzimelor pentru tratamentul tulburărilor SNC şi altor afecţiuni
WO2014144801A1 (en) 2013-03-15 2014-09-18 Agenebio Inc. Methods and compositions for improving cognitive function
EP3827820A1 (en) 2013-03-15 2021-06-02 The Johns Hopkins University Brivaracetam for improving cognitive function
US10131669B2 (en) 2014-07-24 2018-11-20 Pfizer Inc. Pyrazolopyrimidine compounds
HUE044040T2 (hu) 2014-08-06 2019-09-30 Pfizer Imidazopiridazin vegyületek
CN112843005B (zh) 2015-05-22 2023-02-21 艾吉因生物股份有限公司 左乙拉西坦的延时释放药物组合物
JP2017141222A (ja) * 2016-02-09 2017-08-17 国立大学法人帯広畜産大学 パーキンソン病に併発した認知障害の治療剤及びそのスクリーニング方法
TWI877358B (zh) * 2020-04-29 2025-03-21 大陸商廣東東陽光藥業股份有限公司 取代的吡咯烷類化合物及其在藥物中的應用
CN112479966B (zh) * 2020-12-11 2022-05-17 南京工业大学 一种咯利普兰的合成方法

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2413935A1 (de) 1974-03-20 1975-10-16 Schering Ag 4-(polyalkoxy-phenyl)-2-pyrrolidone
US4193926A (en) 1974-03-20 1980-03-18 Schering Aktiengesellschaft 4-(Polyalkoxy phenyl)-2-pyrrolidones
DE2834114A1 (de) * 1978-08-01 1980-02-14 Schering Ag Polyalkoxyphenylpyrrolidone iii, verfahren zu ihrer herstellung und ihre verwendung
DE3438839A1 (de) * 1984-10-19 1986-04-24 Schering AG, 1000 Berlin und 4709 Bergkamen Pharmazeutische praeparate
US5128358A (en) 1988-01-19 1992-07-07 Pfizer Inc. Aryl substituted nitrogen heterocyclic antidepressants
DE3921593A1 (de) 1989-06-28 1991-01-10 Schering Ag Verfahren zur racemattrennung von 4-aryl-2-oxo-pyrrolidin-3-carbonsaeure-ester
GB9009395D0 (en) 1990-04-26 1990-06-20 Orion Yhtymae Oy Cyclic hydroxamic acids and their use
US5935978A (en) 1991-01-28 1999-08-10 Rhone-Poulenc Rorer Limited Compounds containing phenyl linked to aryl or heteroaryl by an aliphatic- or heteroatom-containing linking group
PT100441A (pt) * 1991-05-02 1993-09-30 Smithkline Beecham Corp Pirrolidinonas, seu processo de preparacao, composicoes farmaceuticas que as contem e uso
WO1993007141A1 (en) 1991-10-11 1993-04-15 Smithkline Beecham Corporation Heterocyclic 3-phenylpyrrolidin-2-ones, their preparation and use for the manufacture of a medicament for inhibiting tumor necrosis factor production
CA2114114C (en) 1992-06-15 2005-05-03 Nigel Robert Arnold Beeley Trisubstituted phenyl derivatives as selective phosphodiesterase iv inhibitors
AU673569B2 (en) * 1992-12-02 1996-11-14 Pfizer Inc. Catechol diethers as selective PDE-IV inhibitors
US5814651A (en) 1992-12-02 1998-09-29 Pfizer Inc. Catechol diethers as selective PDEIV inhibitors
TW263495B (enExample) 1992-12-23 1995-11-21 Celltech Ltd
US5665754A (en) * 1993-09-20 1997-09-09 Glaxo Wellcome Inc. Substituted pyrrolidines
JPH07300455A (ja) * 1994-03-08 1995-11-14 Mitsubishi Chem Corp 3−フェニルピロリジン誘導体
KR20040068613A (ko) 1994-03-25 2004-07-31 이소테크니카 인코포레이티드 중수소화된 화합물 이를 포함하는 고혈압 치료용 조성물
US6334997B1 (en) 1994-03-25 2002-01-01 Isotechnika, Inc. Method of using deuterated calcium channel blockers
ATE255413T1 (de) 1994-04-21 2003-12-15 Schering Ag Pde iv-inhibitoren zur behandlung der multiplen sklerose
GB9412383D0 (en) 1994-06-21 1994-08-10 Celltech Ltd Chemical compound
DE19601938A1 (de) 1996-01-12 1997-07-17 Schering Ag Neue Phosphodiesteraseinhibitoren
JPH1072415A (ja) 1996-06-26 1998-03-17 Nikken Chem Co Ltd 3−アニリノ−2−シクロアルケノン誘導体
GB9622386D0 (en) 1996-10-28 1997-01-08 Sandoz Ltd Organic compounds
CA2295106C (en) 1997-06-24 2007-03-13 Nikken Chemicals Co., Ltd. 3-anilino-2-cycloalkenone derivatives
JP3085249B2 (ja) 1997-07-09 2000-09-04 松下電器産業株式会社 ホットプレート
US6403597B1 (en) * 1997-10-28 2002-06-11 Vivus, Inc. Administration of phosphodiesterase inhibitors for the treatment of premature ejaculation
US6258833B1 (en) 1999-12-23 2001-07-10 Icos Corporation Cyclic AMP-specific phosphodiesterase inhibitors
US6372777B1 (en) 1999-12-23 2002-04-16 Icos Corporation Cyclic AMP-specific phosphodiesterase inhibitors
GB0004297D0 (en) 2000-02-23 2000-04-12 Ucb Sa 2-oxo-1 pyrrolidine derivatives process for preparing them and their uses
US6555572B2 (en) 2000-03-16 2003-04-29 Inflazyme Pharmaceuticals Ltd. Benzylated PDE4 inhibitors
WO2002045749A2 (en) 2000-11-02 2002-06-13 Research Foundation Of City University Of New York Methods for stimulating nervous system regeneration and repair by inhibition phosphodiesterase type 4
US6495154B1 (en) * 2000-11-21 2002-12-17 Vivus Inc. On demand administration of clomipramine and salts thereof to treat premature ejaculation
ATE444065T1 (de) 2001-10-16 2009-10-15 Memory Pharm Corp 4(4-alkoxy-3-hydroxyphenyl)-2-pyrrolidon-deriva e als pde-4-hemmer zur behandlung von neurologischen syndromen
SG169900A1 (en) 2003-04-16 2011-04-29 Memory Pharm Corp 4 - (3,4 - disubstituted phenyl) - pyrrolidin-2-one compounds as phosphodiesterase 4 inhibitors

Similar Documents

Publication Publication Date Title
JP2005508961A5 (enExample)
RU2319701C2 (ru) ГЕТЕРОПОЛИЦИКЛИЧЕСКОЕ СОЕДИНЕНИЕ, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, ОБЛАДАЮЩАЯ АНТАГОНИСТИЧЕСКОЙ АКТИВНОСТЬЮ В ОТНОШЕНИИ МЕТАБОТРОПНЫХ ГЛЮТАМАТНЫХ РЕЦЕПТОРОВ mGluR ГРУППЫ I
JP2002508362A5 (ja) 1−置換−1−アミノメチル−シクロアルカン誘導体(=ガバペンチン類縁体)
JP2002502874A5 (enExample)
JP2005505550A5 (enExample)
UA50792C2 (uk) 7<font face="Symbol">a</font>-(<font face="Symbol">x</font>-АМІНОАЛКІЛ)ЕСТРАТРИЄНИ ТА ФАРМАЦЕВТИЧНИЙ ПРЕПАРАТ, ЩО ЇХ МІСТИТЬ
JP2005526144A5 (enExample)
JP2007535595A5 (enExample)
JP2001521187A5 (enExample)
JP2003267957A5 (enExample)
JP2005502658A5 (enExample)
FR2842804B1 (fr) Derives de n-[phenyl(piperidin-2-yl)methyl]benzamide, leur preparation et leur application en therapeutique
JP2005530780A5 (enExample)
JP2002518502A5 (enExample)
KR950032267A (ko) 11,21-비스페닐-19-노르프레그난 유도체
JP2005536503A5 (enExample)
DK1189900T3 (da) Heterocykliske aminopyrrolidinderivater som melatonerge lægemidler
JP2002506864A5 (enExample)
JP2001513567A5 (enExample)
JP2006503056A5 (enExample)
JP2006507324A5 (enExample)
JP2006509753A5 (enExample)
JP2002505294A5 (enExample)
AR048948A1 (es) Una composicion farmaceutica antimicobacteriana
JPH01100169A (ja) 穏和安定薬組成物